BioSpace News Archive

Company’s glass package for retinal implants paves way for further medical advances.

Protalex, Inc. (OTCQB: PRTX), a clinical-stage biopharmaceutical company, today announced that preliminary results from its European Phase 1b open-label, dose-escalation study of PRTX-100 in adult patients with persistent/chronic immune thrombocytopenia (ITP) (PRTX-100-203 Study) will be presented at the upcoming European Hematology Association (EHA) 23rd Annual Meeting being held in Stockholm from June 14-17, 2018

Olympus Corporation of the Americas provides equipment for the CHEST Innovation, Simulation, and Training Center with its charitable contribution

Pharmacy benefit manager’s enhanced program helps payers safely address members’ pain and lower risk of abuse Program helps educate and guide patients prescribed opioids to safely use these powerful drugs

Tasigna lawsuits filed in recent months have highlighted a growing body of scientific evidence linking the leukemia drug to arteriosclerosis, peripheral artery disease, and related vascular conditions.

Dipharma Francis S.r.l., (Dipharma), a leading European manufacturer of Active Pharmaceutical Ingredients, is pleased to communicate that it has completed its previously announced acquisition of Kalexsyn, Inc. (Kalexsyn), a world-class Contract Research Organization (CRO) providing chemistry services to the biotechnology and pharmaceutical industry.

Favorable safety and tolerability profile consistent with Phase 1a data SYNT001 treatment resulted in clinical improvement as measured by Pemphigus Disease Area Index (PDAI) score, with clinical effect persisting beyond the treatment period Rapid reductions in total IgG and circulating immune complex (CIC) levels

Lustgarten Foundation Distinguished Scholar Douglas Fearon, M.D., a professor at Cold Spring Harbor Laboratory (CSHL), has discovered how pancreatic cancer metastasizes to the liver following surgery, as reported in today’s online edition of leading biomedical journal Science.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2018.